Pazopanib (GW786034) In Subjects With Relapsed Or Refractory Multiple Myeloma

A Phase II, Open-Label Study of Pazopanib (GW786034) in Patients With Relapsed or Refractory Multiple Myeloma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00256880

Enrollment

100

Registered

2005-11-22

Start date

2005-01-31

Completion date

2005-12-31

Last updated

2017-01-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Renal Cell

Keywords

Pazopanib(GW786034), Solid Tumors, Myeloma

Brief summary

The purpose of this study is to determine how effective and safe a new investigational drug is in treating patients with relapsed or refractory multiple myeloma. The treatment involves daily dosing. A patient may continue to receive the treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment. During the treatment phase, the patients will undergo regular assessments for safety and clinical response.

Interventions

DRUGGW786034

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Must have diagnosis of relapsed or refractory multiple. * bone marrow function \[ANC (absolute neutrophil count) greater than 1000/mm3\]; platelet count greater than or equal to 75,000/mm3. * renal function (calculated creatinine clearance \>50 mL.min, albumin less than or equal to 500 mg).

Exclusion criteria

* Failed more than 3 prior lines of therapy including stem cell transplant. * Females who are pregnant or nursing. * Unstable blood pressure. * Significant heart conditions or history of thrombosis. * Any unstable, pre-existing major medical condition or history of other cancers. * Have received an investigational drug, chemotherapy, radiation treatment or surgery within 28 days prior to entering the study.

Design outcomes

Primary

Measure	Time frame
Evaluate the safety and tolerability of GW786034 in patients with relapsed or refractory multiple myeloma (MM).	—

Secondary

Measure	Time frame
Evaluate time-to-tumor progression (TTP), time to response, and duration of response. Characterize the pharmacokinetics of GW786034 in patients with MM.	—

Countries

Australia, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026